Updates are available Correction dated 2025-01-07
Click to view Correction: https://doi.org/10.1038/s41416-024-02926-x
-
Authors
Walls, Gerard M. https://orcid.org/0000-0003-0845-9732
Bergom, Carmen https://orcid.org/0000-0002-0886-5055
Mitchell, Joshua D. https://orcid.org/0000-0001-7371-5742
Rentschler, Stacey L. https://orcid.org/0000-0002-1744-1238
Hugo, Geoffrey D.
Samson, Pamela P. https://orcid.org/0000-0003-2448-2123
Robinson, Clifford G. https://orcid.org/0000-0002-1399-9904
- License Information
-
More Information
Article History
Received: 26 May 2024
Revised: 16 October 2024
Accepted: 21 October 2024
First Online: 6 November 2024
Change Date: 16 December 2024
Change Type: Update
Change Details: The original online version of this article was revised: During the proofing process for this article, the authors requested that the rows in Table 1 be sorted by the number present in Column A ‘Author and Year’; this was overlooked by the publisher. Table 1 has been corrected accordingly. The figures within the PDF version of the original article were inadvertently published in black and white; they have been replaced with the original, colour versions provided by the authors at the time of submission.
Change Date: 7 January 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41416-024-02926-x
Competing interests
: GW – Speaker honorarium (Astra Zeneca). CB – no relevant relationships to declare. JM – Research support (Myocardial Solutions, Abbott Laboratories), modest consulting fees (Alnylam, Altathera, Bridgebio, Pfizer and Race Oncology). SR – no relevant relationships to declare. GH – Research support to institution (Varian Medical Systems, ViewRay, Mevion Medical Systems, Siemens Helathineers), consulting fees (Varian), Patents/Royalties/IP (pending patent, Varian Medical Systems). PS – Speaker honoraria (Varian Medical Systems). CR – Research support to institution (Merck, Varian Medical Systems), consulting fees (Varian Medical Systems, AstraZeneca, EMD Serono, Quantaras), Patents/Royalties/IP (Noninvasive imaging and treatment system for cardiac arrhythmias WO 2017078757 A1; U.S. Provisional Application No. 62/598, 162 Entitled System and method for determining segments for ablation), Leadership (Radialogica, EmpNia), Stock/Ownership (Radialogica, Quantaras, EmpNia).
